Neuroinflammation is a hallmark feature of all major neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FTLD), and Huntington's Disease (HD). While each disease has distinct pathological features, the inflammatory response shares common cellular players—primarily microglia and astrocytes—and overlapping molecular pathways. This comparison page synthesizes current understanding of neuroinflammation across these five major neurodegenerative conditions.
Neuroinflammation in neurodegenerative diseases involves:
Neuroinflammation is a hallmark feature of all major neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FTLD), and Huntington's Disease (HD). While each disease has distinct pathological features, the inflammatory response shares common cellular players—primarily microglia and astrocytes—and overlapping molecular pathways. This comparison page synthesizes current understanding of neuroinflammation across these five major neurodegenerative conditions.
Neuroinflammation in neurodegenerative diseases involves:
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTLD | Huntington's Disease |
|---------|-------------------|---------------------|-----|------|---------------------|
| Primary Trigger | Aβ plaques, tau tangles | α-synuclein aggregates | TDP-43, SOD1, C9orf72 | Tau, TDP-43 | Mutant huntingtin (mHTT) |
| Key Microglial Receptors | TREM2, TLR4, CD33 | TLR2, TLR4, NLRP3 | TREM2, CCR2 | TREM2, TLR4 | TREM2, P2X7 |
| Pro-inflammatory Cytokines | IL-1β, IL-6, TNF-α | IL-1β, IL-6, TNF-α | IL-1β, IL-6, TNF-α | IL-1β, IL-6, TNF-α | IL-1β, IL-6, TNF-α |
| Complement Activation | C1q, C3, C4 | C1q, C3 | C1q, C3 | C1q, C3 | C1q, C3 |
| NLRP3 Inflammasome | Activated | Activated | Activated | Activated | Activated |
| Blood-Brain Barrier | Compromised | Compromised | Compromised | Variable | Compromised |
| Astrogliosis | Prominent | Prominent | Prominent | Prominent | Prominent |
| Temporal Onset | Pre-plaque, progressive | Pre-motor, progressive | Early, rapidly progressive | Variable | Pre-manifest, progressive |
| Regional Pattern | Limbic → cortical | Substantia nigra → cortex | Motor cortex → spinal cord | Frontotemporal | Striatum → cortex |
Neuroinflammation follows distinct temporal and spatial progression patterns across neurodegenerative diseases, reflecting the underlying pathology and regional vulnerability of each condition.
In AD, microglial activation can be detected before significant amyloid plaque deposition, suggesting inflammation may play an early pathogenic role[@gerrits2024]. PET imaging using TSPO (translocator protein) ligands reveals progressive inflammation in the entorhinal cortex, hippocampus, and inferior temporal gyrus that correlates with amyloid burden and cognitive decline[@ikonomovic2022]. The inflammatory response intensifies as tau pathology spreads from limbic regions to the neocortex, with microglia transitioning from a protective "disease-associated" phenotype to a more damaging state[@pradier2023]. Longitudinal studies show that neuroinflammation peaks in moderate disease stages and remains elevated throughout progression.
In PD, neuroinflammation precedes motor symptoms by years—PET studies show microglial activation in the substantia nigra and striatum of patients with REM sleep behavior disorder (a prodromal PD marker)[@ouchi2005]. The progression follows a predictable pattern: substantia nigra → basal ganglia → cortical regions, mirroring the spread of alpha-synuclein pathology. Unlike AD, PD shows prominent activation in brainstem regions early, with later cortical involvement corresponding to cognitive decline and dementia[@miron2023].
ALS shows the most rapid progression of neuroinflammation, with microglial activation detected in the motor cortex and spinal cord at disease onset. The inflammatory response follows a "centrifugal" pattern—starting in motor regions and spreading to surrounding areas[@brites2014]. CSF biomarkers show dramatically elevated inflammatory markers (IL-6, TNF-α, MCP-1) at diagnosis, with levels remaining high throughout disease progression. Unlike other neurodegenerative diseases, ALS shows bidirectional inflammation-neurodegeneration: motor neuron death actively drives microglial activation, which in turn accelerates remaining neuron loss.
FTLD shows highly variable neuroinflammation patterns depending on the underlying proteinopathy. FTLD-tau (including PSP and CBD) shows inflammation that closely tracks tau burden, while FTLD-TDP shows inflammation that can exceed the detectable protein load[@wang2024]. The regional distribution matches the characteristic frontotemporal atrophy, with inflammation prominent in the frontal cortex, anterior temporal lobe, and anterior cingulate. Inflammation correlates with behavioral symptoms and disease aggressiveness.
Neuroinflammation in HD is detectable decades before clinical onset[@tai2007]. PET studies in premanifest gene carriers show elevated TSPO binding in the striatum and cortex, indicating early microglial activation. The inflammatory response intensifies as the disease progresses, with maximal activation in the caudate nucleus and putamen corresponding to the most severe neuronal loss. Longitudinal studies show that inflammatory markers (IL-6, CRP) predict disease progression rate and correlate with CAG repeat length.
In AD, neuroinflammation is driven primarily by amyloid-beta (Aβ) plaques and tau neurofibrillary tangles. Microglial activation occurs through:
In PD, neuroinflammation is triggered by:
ALS features neuroinflammation driven by:
FTLD shows neuroinflammation associated with:
HD demonstrates neuroinflammation from:
| Target | Drug Class | Disease Context | Status |
|--------|-----------|-----------------|--------|
| NLRP3 | Small molecule inhibitors | AD, PD, ALS | Preclinical |
| TREM2 | Agonistic antibodies | AD | Phase 2 |
| CD33 | Blocking antibodies | AD | Preclinical |
| TNF-α | Etanercept (peripheral) | PD | Failed trials |
| IL-1β | Canakinumab | AD | Phase 2/3 |
| CSF1R | Small molecule inhibitors | ALS, HD | Phase 1/2 |
| Trial ID | Agent | Target | Disease | Phase | Status |
|----------|-------|--------|---------|-------|--------|
| NCT02055027 | TWEAK抑制剂 | NLRP3/TAK1 | ALS | 2 | Completed |
| NCT01703091 | Etanercept | TNF-α | PD | 2 | Completed |
| NCT02555384 | TREM2激动剂 | TREM2 | AD | 1b | Completed |
| NCT02423122 | Sargramostim | GM-CSF | AD | 2 | Completed |
| NCT03943264 | Anifrolumab | IFN-α receptor | AD | 2 | Recruiting |
| NCT04577382 | Buntanetap | TNF-α, IL-1β, IL-6 | PD | 2a | Recruiting |
| NCT05663498 | Lomeguatrib + Temozolomide | MGMT, DNA repair | ALS | 1 | Recruiting |
| NCT04057834 | CNM-Au8 | NAD+ metabolism | ALS/PD | 2 | Active |
TREM2 Agonists (AD):
The NLRP3 inflammasome represents a critical molecular hub linking protein aggregation to neuroinflammation across neurodegenerative diseases. This cytosolic protein complex detects danger signals and activates caspase-1, which processes pro-IL-1beta and pro-IL-18 into their active forms.
Activation Triggers: In AD, Abeta oligomers directly activate NLRP3 through potassium efflux and ROS generation. In PD, alpha-synuclein aggregates trigger inflammasome assembly via TLR2/4 signaling. In ALS, TDP-43 and SOD1 aggregates activate the inflammasome. In HD, mutant huntingtin activates NLRP3 through mitochondrial dysfunction and ROS.
Downstream Effects: Activated caspase-1 leads to pyroptosis, a highly inflammatory form of cell death characterized by gasdermin pore formation and cell lysis. NLRP3 activation also amplifies inflammatory signaling through ASC speck formation, which can spread between cells.
Therapeutic Targeting: Small-molecule NLRP3 inhibitors (like MCC950) have shown efficacy in preclinical models of AD, PD, and ALS. Several NLRP3 inhibitors have advanced to clinical testing for inflammatory conditions, with potential for repurposing in neurodegeneration.
Synaptic Pruning: Complement component C1q tags synapses for removal by microglia through the classical complement pathway. In neurodegeneration, excessive C1q labeling leads to abnormal synaptic elimination. C1q is upregulated in AD, PD, and ALS, contributing to early synaptic loss.
C3 and Microglial Phagocytosis: C3, the central complement component, is released by A1 neurotoxic astrocytes. C3 binds to neurons and promotes microglial phagocytosis through complement receptor 3 (CR3). Blocking C3-CR3 signaling reduces microglial synapse removal in models.
Therapeutic Implications: C1q inhibitors aim to reduce pathological synaptic pruning, while C3 inhibitors (pegylated C3 inhibitor) may protect neurons from complement-mediated damage.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a surface receptor on microglia that regulates phagocytosis, inflammatory responses, and metabolic adaptation. TREM2 recognizes lipids, lipoproteins, and protein aggregates including Abeta, alpha-synuclein, and TDP-43. The R47H variant significantly increases AD risk (~3-fold) by impairing ligand binding and reducing phagocytic function. TREM2 variants also increase FTD risk.
TREM2 agonistic antibodies aim to enhance microglial function and Abeta clearance and have entered clinical trials for AD.
Single-cell RNA sequencing has identified novel microglial and astrocyte subtypes beyond the classical M1/M2 paradigm:
The relationship between neuroinflammation and protein aggregation is bidirectional:
Inflammation-Driven Aggregation: TNF-alpha promotes Abeta oligomerization. IL-1beta accelerates tau pathology. In PD, neuroinflammation promotes alpha-synuclein phosphorylation and aggregation through kinase activation.
Aggregation-Driven Inflammation: Protein aggregates serve as DAMPs that activate TLR2, TLR4, and NLRP3, initiating inflammatory cascades. This creates positive feedback where aggregation drives inflammation, which promotes further aggregation.
Dysbiosis (altered gut microbiota) is observed in AD, PD, ALS, and FTD. Specific bacterial metabolites, such as short-chain fatty acids (SCFAs), modulate microglial maturation and function. In PD, alpha-synuclein pathology appears in the enteric nervous system before the brain, suggesting prion-like spread. Probiotics, prebiotics, and fecal microbiota transplantation are being explored to modulate neuroinflammation through the gut-brain axis.
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|----------------------|
| Primary Glial Response | Microglia, astrocytes | Microglia | Activated microglia | Astrocytes, microglia | Microglia, astrocytes |
| Key Cytokines | IL-1beta, IL-6, TNF-alpha | IL-1beta, TNF-alpha | IL-6, IL-1beta, TNF-alpha | IL-6, TNF-alpha | IL-1beta, IL-6, TNF-alpha |
| Inflammasome | NLRP3 | NLRP3 | NLRP3 | NLRP3 | NLRP3 |
| Reactive Astrocytes | A1 phenotype | A2 phenotype | A1 phenotype | Variable | A1/A2 mixed |
| Peripheral Immune | Monocyte infiltration | Monocyte infiltration | T-cell infiltration | Minimal | Minimal |
| Blood-Brain Barrier | Disrupted | Disrupted | Disrupted | Variable | Disrupted |
| Microglial Markers | IBA1, CD68, TREM2 | IBA1, CD68 | IBA1, CD68, p2Y12 | IBA1, GFAP | IBA1, CD68 |
| Astrocyte Markers | GFAP, C3 (A1) | GFAP, S100beta | GFAP, C3 | GFAP | GFAP, S100beta |
| Complement Activation | C1q, C3 elevated | C3 elevated | C1q, C3 | Variable | C3 elevated |
| Pattern Recognition | TLR2, TLR4, CD36 | TLR2, TLR4 | TLR2, TLR4 | TLR2 | TLR2, TLR4 |